2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim H. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 2024, 14: 30536. PMID: 39690170, PMCID: PMC11652651, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchConceptsGEP-NEN patientsGastroenteropancreatic neuroendocrine neoplasmsOverall survivalGEP-NENsTreatment patternsSystemic therapyNeuroendocrine neoplasmsAssociated with improved survivalLow-grade diseaseNational Cancer DatabaseLonger overall survivalSite-specific incidenceDisease specific factorsG3 NENSurgical resectionCancer DatabaseImproved survivalLow-stageCox regressionImprove outcomesPatientsIncidence increasesInternational guidelinesInvestigate incidenceSurvival
2019
A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.Peer-Reviewed Original ResearchDisease control rateMetastatic colorectal cancerTAS-102Progressive diseaseDay 1Thymidine phosphorylase inhibitorRefractory metastatic colorectal cancerDose-escalating studyECOG PS 0Phase II doseEfficacy of oxaliplatinUsual laboratory parametersEligible patientsEvaluable patientsMeasurable diseaseUnexpected AEsStarting doseTreatment discontinuationPS 0Improved survivalLaboratory parametersOral combinationColorectal cancerPatient populationControl rate